EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Design, Synthesis, and Evaluation of Naphthyl Pyrazino‐Pyrido‐Pyrimidinones Targeting the Phosphoinositide 3‐Kinase/Alpha‐Serine/Protein Kinase B/Mammalian Target of Rapamycin Pathway

Marcelo F Marchiori iD, Gabriel da Silva iD, Daniel F Kawano iD, Andréia M Leopoldino iD, Enrique Madruga iD, Ana Martinez iD, Ivone Carvalho iD

ChemistryOpen · 2026

DOI: 10.1002/open.202500615 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ChemistryOpen, 2026. Verfasst von Marcelo F Marchiori und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences of Ribeirão Preto - University of São Paulo, Ribeirão Preto, Brazil. Hauptthemen laut MEDLINE: Drug Design, TOR Serine-Threonine Kinases, Antineoplastic Agents, Proto-Oncogene Proteins c-akt. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundação de Amparo à Pesquisa do Estado de São Paulo, Conselho Nacional de Desenvolvimento Científico e Tecnológico, Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer remains a leading global cause of death and a major public health concern, with rising incidence and mortality rates. Current treatments are often limited by tumor complexity and heterogeneity, emphasizing the need for novel, targeted, and personalized therapies. Aberrant activation of the phosphoinositide 3‐kinase/alpha‐serine/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway plays a key role in cancer development, making it an attractive therapeutic target. In this study, we performed in silico and in vitro analyses to assess the antitumor potential of two pyrazino‐pyrido[2,3‐d]pyrimidine‐5,7‐dione Series (A and B) across various cancer cell lines, focusing on possible PI3K/AKT/mTOR inhibition. Guided by these results, we designed a new Series (C) with a fixed C‐9 naphthyl group and variable C‐6 substitutions. The compounds were synthesized via an optimized one‐pot process followed by intramolecular cyclization. Molecular docking and biological assays revealed notable antitumor activity for Series C, particularly for compounds 3 and 4, in BT20, HGC, and CAL‐27 cell lines, while showing selectivity over normal fibroblasts (GNP5). These compounds also affected cell cycle progression and phosphorylation of key proteins involved in autophagy and survival (ULK1, LC3, p‐AKT, p‐STAT3). Overall, this study introduces a promising new scaffold with potent, selective antitumor properties.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug DesignTOR Serine-Threonine KinasesAntineoplastic AgentsProto-Oncogene Proteins c-aktPyrimidinonesPyrazinesProtein Kinase InhibitorsHumansMolecular Docking SimulationCell Line, TumorPhosphatidylinositol 3-KinasesSignal TransductionCell ProliferationStructure-Activity Relationship

Stichwörter der Autor:innen

antitumoral evaluationcancermolecular dockingphosphoinositide 3‐kinase/alpha‐serine/protein kinase B/mammalian target of rap…pyrazino‐pyrido[2,3‐d]pyrimidine‐5,7‐dione

Substanzen

TOR Serine-Threonine KinasesAntineoplastic AgentsProto-Oncogene Proteins c-aktPyrimidinonesPhosphatidylinositol 3-KinasesPyrazinesMTOR protein, humanProtein Kinase Inhibitors

Autor:innen und Institutionen

  • School of Pharmaceutical Sciences of Ribeirão Preto - University of São Paulo, Ribeirão Preto, Brazil.
  • Faculty of Pharmaceutical Sciences, State University of Campinas, Campinas, Brazil.
  • Centro de Investigaciones Biológicas (CIB) del Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain.
  • Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.

ORCID-Profile: Marcelo F Marchiori, Gabriel da Silva, Daniel F Kawano, Andréia M Leopoldino, Enrique Madruga, Ana Martinez, Ivone Carvalho

Förderung

  • Fundação de Amparo à Pesquisa do Estado de São Paulo
  • Conselho Nacional de Desenvolvimento Científico e Tecnológico
  • Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
  • Instituto de Salud Carlos III
  • Ministerio de Ciencia, Innovación y Universidades

Zitieren

APA

Marchiori, M. F., da Silva, G., Kawano, D. F., Leopoldino, A. M., Madruga, E., Martinez, A., & Carvalho, I. (2026). Design, Synthesis, and Evaluation of Naphthyl Pyrazino‐Pyrido‐Pyrimidinones Targeting the Phosphoinositide 3‐Kinase/Alpha‐Serine/Protein Kinase B/Mammalian Target of Rapamycin Pathway. ChemistryOpen. https://doi.org/10.1002/open.202500615

Vancouver

Marchiori MF, da Silva G, Kawano DF, Leopoldino AM, Madruga E, Martinez A, et al. Design, Synthesis, and Evaluation of Naphthyl Pyrazino‐Pyrido‐Pyrimidinones Targeting the Phosphoinositide 3‐Kinase/Alpha‐Serine/Protein Kinase B/Mammalian Target of Rapamycin Pathway. ChemistryOpen. 2026. doi:10.1002/open.202500615

BibTeX
@article{Marchiori2026,
  author = {Marchiori, Marcelo F and da Silva, Gabriel and Kawano, Daniel F and Leopoldino, Andréia M and Madruga, Enrique and Martinez, Ana and Carvalho, Ivone},
  title = {Design, Synthesis, and Evaluation of Naphthyl Pyrazino‐Pyrido‐Pyrimidinones Targeting the Phosphoinositide 3‐Kinase/Alpha‐Serine/Protein Kinase B/Mammalian Target of Rapamycin Pathway},
  journal = {ChemistryOpen},
  year = {2026},
  doi = {10.1002/open.202500615}
}
Kostenlos starten →